Latest Asx Disclosures News

Botanix Pharmaceuticals has clarified that recent share price movements are linked to a rumored US executive order on drug pricing, confirming no undisclosed material information. The company reassures investors of compliance with ASX disclosure rules amid market speculation.

Mayne Pharma Group has acknowledged a delayed filing of a director's interest notice due to administrative oversight and is taking steps to reinforce compliance with ASX disclosure rules.

Tivan Limited has responded to ASX inquiries about a social media post by its executive chair concerning fluorite exploration, affirming compliance with disclosure rules and pending assay results.

Yowie Group Ltd has responded to ASX queries detailing a significant revenue impact from reduced store facings and clarified complex loan arrangements with Keybridge Capital Limited amid ongoing solvency concerns.

Dateline Resources has gained critical U.S. regulatory approval for its Colosseum Gold-REE Project, unlocking rare earth exploration rights and pursuing an OTCQB listing to engage American investors.

Assetora Limited has dramatically reduced its net liabilities and strengthened its balance sheet through strategic capital raises and debt conversions, while unveiling a comprehensive rebrand and leadership expansion to drive its next growth phase.

Aldoro Resources has responded to an ASX price query by releasing partial exploration assay results after a significant share price jump, citing laboratory delays and confidentiality concerns as reasons for prior nondisclosure.

Bendigo and Adelaide Bank clarifies a modest 5.8% variance in half-year cash earnings against market forecasts, confirming no material surprise and compliance with ASX disclosure rules.

Laramide Resources Ltd. has acknowledged a delayed filing of a director's interest notice due to internal illness, prompting an ASX inquiry and procedural upgrades to prevent future lapses.

AUCyber Limited confirms control has passed to 5GN following a substantial holding disclosure, with the Board unanimously recommending shareholders accept 5GN's last and final offer closing on 17 February 2025.

Epsilon Healthcare's December 2023 quarterly report reveals significant boardroom conflict and governance breaches, yet operational segments show promising growth.

Gullewa Limited reports a robust cash balance of $9.087 million at the end of December 2024, supported by strong financing inflows despite ongoing exploration expenditures. The company’s quarterly cash flow highlights its strategic financial management as it advances key tenements in Western Australia.